Ticagrelor Versus Clopidogrel in Large Vessel Ischemic Stroke - Trial NCT06120725
Access comprehensive clinical trial information for NCT06120725 through Pure Global AI's free database. This Phase 3 trial is sponsored by Kafrelsheikh University and is currently Recruiting. The study focuses on Ischemic Stroke. Target enrollment is 580 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Kafrelsheikh University
Timeline & Enrollment
Phase 3
Sep 01, 2021
Nov 05, 2023
Primary Outcome
Rate of Hemorrhagic transformation of the Infarct,Rate of Peripheral Bleeding using PLATO classification,rate of drug adverse effects
Summary
Along with the current clinical trial, the efficacy and safety of 180 mg loading dose of
 ticagrelor administered within 24 hours of first-ever large-vessel ischemic stroke compared
 to 300 mg clopidogrel were assessed through NIHSS, mRS, duration of hospital stay, and
 possible adverse effects.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06120725
Non-Device Trial